SCHEMBL3205489

SCHEMBL3205489

Brc1ccc2[nH]nnc2n1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.35
METAP2 P50579 2/20 0.35
CSNK2A1 P68400 1/20 0.35
DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421802 0.74 NOS1 (0.35) NOS1
SCHEMBL45555 0.74 KDM4E (0.35) NOS1
SCHEMBL9996915 0.74 GAA (0.41) NOS1
SCHEMBL31224907 0.69
SCHEMBL17326272 0.69 TRPA1 (0.33) DYRK1A
SCHEMBL19579757 0.68 KDM4E (0.43)
SCHEMBL8014109 0.67 KDM4E (0.43) NOS1
SCHEMBL31224914 0.67 ADORA2A (0.32)
SCHEMBL31224733 0.65 HPGD (0.43)
SCHEMBL3050731 0.65 ALDH1A1 (0.44) NOS1METAP2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100047321-A1 SILVER ANTIMICROBIAL COMPOSITION AND USE EASTMAN KODAK COMPANY 2010-02-25 US claimed
WO-2010021662-A2 SILVER ANTIMICROBIAL COMPOSITION AND USE EASTMAN KODAK COMPANY (US) 2010-02-25 WO claimed
EP-0566075-B1 Silver halide photographic emulsions utilizing low-dye sensitizations with incorporated fog suppressants EASTMAN KODAK CO (US) 1998-12-09 EP claimed
EP-0566075-A1 Silver halide photographic emulsions utilizing low-dye sensitizations with incorporated fog suppressants EASTMAN KODAK COMPANY (US) 1993-10-20 EP claimed
EP-4676926-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS ThirtyFiveBio Limited (GB) 2026-01-14 EP disclosed
WO-2024184650-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. ThirtyFiveBio Limited (GB) 2024-09-12 WO disclosed
CN-109311878-B Triazolopyridines as gamma-secretase modulators 豪夫迈·罗氏有限公司 2022-05-24 CN disclosed
US-10981879-B2 Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-20 US disclosed
US-10407422-B2 Triazolopyridine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-10 US disclosed
US-10316035-B2 Triazolopyridine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2019-06-11 US disclosed
US-20190031623-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2019-01-31 US disclosed
US-20190023701-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2019-01-24 US disclosed
US-20100047321-A1 SILVER ANTIMICROBIAL COMPOSITION AND USE EASTMAN KODAK COMPANY 2010-02-25 US disclosed
WO-2010010189-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2010-01-28 WO disclosed
US-20090215817-A1 Novel Triazolopyridine Compounds for the Treatment of Inflammation PFIZER INC 2009-08-27 US disclosed
US-20090209577-A1 Novel Triazolopyridine Compounds PFIZER INC. (US) 2009-08-20 US disclosed
EP-0566075-B1 Silver halide photographic emulsions utilizing low-dye sensitizations with incorporated fog suppressants EASTMAN KODAK CO (US) 1998-12-09 EP disclosed
EP-0566075-A1 Silver halide photographic emulsions utilizing low-dye sensitizations with incorporated fog suppressants EASTMAN KODAK COMPANY (US) 1993-10-20 EP disclosed
US-5210014-A Benzimidazole carbocyanine dyes, storage stability EASTMAN KODAK COMPANY (US) 1993-05-11 US disclosed
EP-0506077-A1 Mid-green sensitizing dyes for photographic materials EASTMAN KODAK COMPANY (US) 1992-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10316035-B2 Triazolopyridine inhibitors of myeloperoxidase EPX, MPO, SERPINB1 NOS1 477/4885METAP2 221/4885CSNK2A1 1844/4885
US-20190031623-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 NOS1 1221/4885METAP2 154/4885CSNK2A1 1627/4885
US-20190023701-A1 TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 NOS1 619/4885METAP2 135/4885CSNK2A1 2093/4885
US-20090209577-A1 Novel Triazolopyridine Compounds MAP3K2, MAP3K5, MAP3K9 NOS1 134/4885METAP2 1505/4885CSNK2A1 713/4885
US-20090215817-A1 Novel Triazolopyridine Compounds for the Treatment of Inflammation TNF, MAP3K2, MAP3K5 NOS1 121/4885METAP2 1761/4885CSNK2A1 864/4885
US-10407422-B2 Triazolopyridine inhibitors of myeloperoxidase EPX, MPO, SERPINB1 NOS1 619/4885METAP2 135/4885CSNK2A1 2093/4885
US-10981879-B2 Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase EPX, MPO, SERPINB1 NOS1 1221/4885METAP2 154/4885CSNK2A1 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.